Anti-CLCN2 Antibody (aa738-751) IHC-plus; CLCN2; Chloride channel protein 2; Chloride channel 2; ClC-2; CIC-2; CLC2; EGI3; EJM6; ECA2; ECA3; EGMA; EJM8; EGI11; Human CLCN2

For Research Use Only. Not for use in diagnostic procedures.

Polyclonal

Goat

Human CLCN2. This antibody is expected to recognize all reported isoforms (NP_004357.3; NP_001164558.1; NP_001164559.1; NP_001164560.1).

Immunoaffinity Purified

Tris-buffered saline, pH 7.3, 0.5% BSA, 0.02% sodium azide

0.5 mg/ml (lot specific)

Store at -20 degree C. Minimize freezing and thawing.

Small volumes of anti-CLCN2 antibody vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Clcn2, a member of the CLC chloride channel subfamily, has been implicated in the regulation of cell volume and neuronal excitability.

Subfamily:-Chloride-channel---CLC">Family: Ion channel
Subfamily: Chloride channel - CLC

Immunohistochemistry (IHC - Paraffin)

IHC-P (3.75 - 7.5 ug/ml)

Anti-CLCN2 antibody IHC of human uterus. Immunohistochemistry of formalin-fixed, paraffin-embedded tissue after heat-induced antigen retrieval. Antibody concentration 3.75 ug/ml.

95,399 Da

chloride channel, voltage-sensitive 2

chloride channel protein 2; chloride channel 2

Chloride channel protein 2

ClC-2??[Similar Products]

CLCN2_HUMAN

This gene encodes a voltage-gated chloride channel. The encoded protein is a transmembrane protein that maintains chloride ion homeostasis in various cells. Defects in this gene may be a cause of certain epilepsies. Four transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Mar 2012]

CLCN2: Voltage-gated chloride channel. Chloride channels have several functions including the regulation of cell volume; membrane potential stabilization, signal transduction and transepithelial transport. Defects in CLCN2 are associated with susceptibility to epilepsy, idiopathic generalized type 11 (EIG11). A disorder characterized by recurring generalized seizures in the absence of detectable brain lesions and/or metabolic abnormalities. Generalized seizures arise diffusely and simultaneously from both hemispheres of the brain. Defects in CLCN2 are associated with juvenile absence epilepsy type 2 (JAE2). JAE is a subtype of idiopathic generalized epilepsy (IGE) characterized by onset occurring around puberty, absence seizures, generalized tonic- clonic seizures (GTCS), GTCS on awakening and myoclonic seizures. Defects in CLCN2 are associated with juvenile myoclonic epilepsy type 8 (EJM8). A subtype of idiopathic generalized epilepsy. Patients have afebrile seizures only, with onset in adolescence (rather than in childhood) and myoclonic jerks which usually occur after awakening and are triggered by sleep deprivation and fatigue. Belongs to the chloride channel (TC 2.A.49) family. ClC-2/CLCN2 subfamily. 3 isoforms of the human protein are produced by alternative splicing.

Protein type: Channel, chloride; Transporter, ion channel; Membrane protein, integral; Membrane protein, multi-pass; Transporter

Chromosomal Location of Human Ortholog: 3q27.1

Cellular Component: plasma membrane

Molecular Function: voltage-gated chloride channel activity

Biological Process: retina development in camera-type eye; transport; transmembrane transport

Disease: Epilepsy, Idiopathic Generalized, Susceptibility To, 11; Leukoencephalopathy With Ataxia

All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.

While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.